ドキソルビシンの世界市場分析:用途別(卵巣がん、多発性骨髄腫、カポジ肉腫、白血病、骨肉腫、乳房、子宮内膜がん、胃がん、肝臓がん、腎臓がん、他のがん)、セグメント予測、2013 – 2024

Grand View Researchが出版した調査資料(GVIEW707263)
◆英語タイトル:Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024
◆商品コード:GVIEW707263
◆発行会社(調査会社):Grand View Research
◆発行日:2016年11月23日
◆ページ数:84
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥874,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,094,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、ドキソルビシンの世界市場について調査・分析し、ドキソルビシンの世界市場動向、ドキソルビシンの世界市場規模、市場予測、セグメント別ドキソルビシン市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global doxorubicin market was valued at USD 0.81 billion in 2015 and is expected to reach a value of USD 1.38 billion by 2024, according to a new report by Grand View Research, Inc. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.
The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: -

Leukemia 60,140

Breast cancer 2,46,660

Endometrial cancer 60,050

Gastric cancer 26,370

Liver cancer 39,230

Kidney Cancer 62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

Further Key Findings from the Study Suggest:

In 2015, breast cancer is the largest application of doxorubicin market, having a share of around 21.1%. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.

Liver cancer segment is the fastest growing application in this sector. The growing demand for the drug in combination and mono chemotherapies to treat liver cancer over other anticancer drugs is one of the crucial factors that is expected to boost the industry growth.

In 2015, North America held majority of market share of over 48.8% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.

Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.

Some of the key market players are Sun Pharmaceutical Industries Ltd., Pfizer, Inc., Cipla, Inc., Cadila Pharmaceuticals, and SRS Pharmaceuticals Pvt. Ltd.

【レポートの目次】

Table of Contents

Chapter 1 Executive Summary
Chapter 2 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing number of market players
3.1.1.2 Increasing application of doxorubicin
3.1.1.3 Growing number of cancer cases
3.1.2 Market restraint analysis
3.1.2.1 Supply demand gap
3.2 Penetration & Growth Prospect Mapping
3.3 Doxorubicin Market- SWOT Analysis, by Factor (Political &Legal, Economic, and Technological)
3.4 Industry Analysis – Porter’s
Chapter 4 Market Categorization 1: Application Estimates & Trend Analysis
4.1 Doxorubicin Market: ApplicationMovement Analysis
4.2 Ovarian Cancer
4.2.1 Ovarian cancer market estimates and forecasts, 2013 – 2024 (USD Million)
4.3 Multiple Myeloma
4.3.1 Multiple myeloma market estimates and forecasts, 2013 – 2024 (USD Million)
4.4 Kaposi Sarcoma
4.4.1 Kaposi Sarcoma market estimates and forecasts, 2013 – 2024 (USD Million)
4.5 Leukemia
4.5.1 Leukemia market estimates and forecasts, 2013 – 2024 (USD Million)
4.6 Bone sarcoma
4.6.1 Bone sarcoma market estimates and forecasts, 2013 – 2024 (USD Million)
4.7 Breast cancer
4.7.1 Breast cancer market estimates and forecasts, 2013 – 2024 (USD Million)
4.8 Endometrial cancer
4.8.1 Endometrial cancer market estimates and forecasts, 2013 – 2024 (USD Million)
4.9 Gastric cancer
4.9.1 Gastric cancer market estimates and forecasts, 2013 – 2024 (USD Million)
4.10 Liver cancer
4.10.1 Liver cancer market estimates and forecasts, 2013 – 2024 (USD Million)
4.11 Kidney cancer
4.11.1 Kidney cancer market estimates and forecasts, 2013 – 2024 (USD Million)
4.12 Other cancer
4.12.1 Other cancer market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 5 Market Categorization 4: Regional Estimates & Trend Analysis
5.1 Doxorubicin Market Share by Region, 2013 & 2024
5.2 North America
5.2.1 North America doxorubicin market estimates and forecasts, by application 2013 – 2024(USD Million)
5.2.2 U.S.
5.2.2.1 U.S. doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.2.3 Canada
5.2.3.1 Canada doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.3 Europe
5.3.1 Europe doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.3.2 Germany
5.3.2.1 Germany doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.3.3 UK
5.3.3.1 UK doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.4.2 Japan
5.4.2.1 Japan doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.4.3 China
5.4.3.1 China doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.5 Latin America
5.5.1 Latin America doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.6 MEA
5.6.1 MEA doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa doxorubicin market estimates and forecasts, by application 2013 – 2024 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Pfizer, Inc.
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Product benchmarking
6.3.1.4 Strategic initiatives
6.3.2 Sun Pharmaceutical Industries Ltd.
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 Cipla, Inc.
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 Cadila Pharmaceuticals
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.5 SRS PHARMACEUTICALS PVT. LTD.
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 Janssen Products, LP
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives

List of Figures

FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT analysis, by factor (Political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Doxorubicin Market: Application outlook key takeaways
FIG. 10 Doxorubicin Market: Application movement analysis
FIG. 11 Ovarian market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 12 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 13 Kaposi sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 14 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 15 Bone sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 16 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 17 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 18 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 19 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 20 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 21 Other cancer application market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 22 Regional market place: Key takeaways
FIG. 23 Regional outlook, 2015 & 2024
FIG. 24 North America doxorubicin market estimates and forecasts,by application, 2013-2024(USD Million)
FIG. 25 U.S. doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
FIG. 26 Canada doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
FIG. 27 Europe doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
FIG. 28 Germany doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
FIG. 29 UK doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
FIG. 30 Asia Pacific doxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
FIG. 31 Japan doxorubicin market estimates and forecasts, by application, 2013- 2024(USD Million)
FIG. 32 Chinadoxorubicin market estimates and forecasts, by application, 2013 - 2024(USD Million)
FIG. 33 Latin America doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
FIG. 34 Brazildoxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
FIG. 35 Mexico doxorubicin market estimates and forecasts,by application, 2013 - 2024(USD Million)
FIG. 36 MEA doxorubicin market estimates and forecasts,by application 2013-2024(USD Million)
FIG. 37 South Africa doxorubicin market estimates and forecasts,by application, 2013 - 2024(USD Million)
FIG. 38 Strategy framework
FIG. 39 Participant categorization

List of Tables

Table 1 Approved doxorubicin products, by approval date and company name
Table 2 Estimated number of cancer cases and deaths, by type in 2016
Table 3 Cancer Prevalence, by type and region in 2012
Table 4 Number of patients treated using doxorubicin, 2012
Table 5 North America doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 6 Estimated new cases of cancer, by type and age, 2015
Table 7 U.S. doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 8 Canada doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 9 Europe doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 10 UK doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 11 Germany doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 12 Asia Pacific doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 13 Number of cancer cases by site in 2015
Table 14 Japan doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 15 China doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 16 Latin America doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 17 Brazil doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 18 Mexico doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 19 MEA doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 20 South Africa doxorubicin market, by application, 2013 - 2024 (USD Million)

★調査レポート[ドキソルビシンの世界市場分析:用途別(卵巣がん、多発性骨髄腫、カポジ肉腫、白血病、骨肉腫、乳房、子宮内膜がん、胃がん、肝臓がん、腎臓がん、他のがん)、セグメント予測、2013 – 2024] (コード:GVIEW707263)販売に関する免責事項を必ずご確認ください。
★調査レポート[ドキソルビシンの世界市場分析:用途別(卵巣がん、多発性骨髄腫、カポジ肉腫、白血病、骨肉腫、乳房、子宮内膜がん、胃がん、肝臓がん、腎臓がん、他のがん)、セグメント予測、2013 – 2024]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆